Cord blood transplant with added white blood cells for high-risk leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding extra white blood cells (granulocytes) to a cord blood transplant can improve outcomes for people with poor-risk leukemia. It's for patients aged 16 to 55 who have certain genetic mutations or not fully responding to chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 16 and 55 years old.
- You must have a type of acute myeloid leukemia (AML) or MDS that is considered high-risk.
- Your cancer must have genetic features like a TP53 mutation or certain chromosome changes.
- A suitable cord blood unit must be available for transplant.
- Your heart, lungs, kidneys, and liver must work well enough for transplant.
- You must be willing to use effective contraception during and for 12 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
This trial tests a stem cell transplant (using donor cells) for people with a high-risk form of acute myeloid leukemia called CBF-AML. The goal is to see if this transplant can help patients who have a higher chance of the leukemia coming back.
This Phase 2 trial studies using a cord blood transplant after finding it is risky enough that standard treatment may not be sufficient. It may help certain children and young adults with specific leukemia, lymphoma, and some non-cancer blood/immune or inherited disorders who do not have a well-matched donor available in time.
This Phase 2 study tests using donated cord blood to treat certain adult blood cancers that are at high risk of coming back. It may help strengthen the body’s ability to rebuild blood and fight the cancer after intensive treatment.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.